Everything below concerns tesamorelin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
=== Food-induced dose dumping (FIDD) === Food intake produces dynamic changes in digestion and pharmacokinetics through a variety of mechanisms, which can produce an unintended release of modified-release dosages under certain circumstances. Usually, high fat diets are the most associated with this phenomenon, but there is evidence that standard-composition food can cause this even in immediate release formulations, such as the case of methylphenidate. Some of the mechanisms involved in FIDD are:
== Early life and education == Meinrad Busslinger was born on 30 July 1952 in Gebenstorf, Switzerland. He grew up in the Swiss town of Zug, where he obtained his grammar school education. From 1972 to 1976, he studied natural sciences at the Swiss Federal Institute of Technology (ETH Zurich), where he majored in biochemistry. During his PhD studies (1976–1981), Busslinger discovered important regulatory elements involved in the transcriptional control of gene expression by investigating the regulation of sea urchin histone genes. He performed his PhD work under the supervision of Max L. Birnstiel at the University of Zurich, from where he received a PhD degree in molecular biology in 1981.
As treasurer, Kennedy sought to refinance portions of Louisiana's debt from Hurricanes Katrina and Rita as interest rates decreased. He worked with the state legislature and several governors' offices to negotiate each refinancing. In 2004, Kennedy told the state legislature that he could save more than $1.4 billion by refinancing the state's debt. He noted that he had sent Governor Kathleen Blanco several letters about refinancing that went unanswered. In 2011, Kennedy announced that Lafayette and Livingston Parishes had saved $11 million by refinancing. By 2013, Kennedy said he had "refinanced virtually all of the state's debt". In 2014, Kennedy worked to refinance $229 million in bond debt. The project faced delays because of a disagreement with Governor Bobby Jindal's office over accounting practices. Jindal's team claimed Kennedy was "unnecessarily holding up" progress on many construction projects, but Kennedy maintained that Jindal's accounting practices potentially violated federal anti-fraud laws. The two sides eventually compromised and the deal moved ahead, saving Louisiana $12 million. By the end of 2014, Kennedy had saved Louisiana a total of more than $600 million by refinancing debt. In 2015, Kennedy saved Louisiana $109 million over 26 years by refinancing a $649 million loan that funded a highway project.
Nalorphine (INNTooltip International Nonproprietary Name; also known as N-allylnormorphine; brand names Lethidrone and Nalline) is a mixed opioid agonist–antagonist with opioid antagonist and analgesic properties. It was introduced in 1954 and was used as an antidote to reverse opioid overdose and in a challenge test to determine opioid dependence. Nalorphine was the second opioid antagonist to be introduced, preceded by nalodeine (N-allylnorcodeine) in 1915 and followed by naloxone in 1960 and naltrexone in 1963. Due to potent activation of the κ-opioid receptor, nalorphine produces side effects such as dysphoria, anxiety, confusion, and hallucinations, and for this reason, is no longer used medically.
Sources: en.wikipedia.org
=== Lozano-Fernandez et al. (2019) === In 2019, similar to previous studies, such as Oakley et al. (2013) and Schwentner et al. (2017), Lozano-Fernandez et al. divided Pancrustacea into Allotriocarida, along with Oligostraca and Multicrustacea, as the three main divisions of subphylum Pancrustacea, embracing the traditional crustaceans and the hexapods (including insects). Lozano-Fernandez et al. also proposed a new group Athalassocarida for the Labiocarida plus Branchiopoda clade (derived from "Athalasso" [Greek: nonmarine] and "carida" [Greek: prawn]), thereby referring to a grouping of pancrustaceans where all extant members either live in nonmarine settings or reverted to a marine life-style secondarily.
yr, but in the past 40 years, the experimental scene has been dominated by the KamiokaNDE experiment and its successor Super-Kamiokande. The construction of KamiokaNDE experiment under the direction of Masatoshi Koshiba was completed in 1983. The detector was a cylindrical tank (16 m in height and 15.6 m in diameter) containing 3,000 tons of pure water, equipped with about 1,000 photomultiplier tubes (PMTs) arranged on the lateral surface. It was located in the Kamioka zinc mine (near the city of Hida, Gifu Prefecture, Japan). The photomultipliers detected Cherenkov light, emitted by charged particles traversing the water at speeds greater than the speed of light in the medium. KamiokaNDE was able to set stringent lower limits on the proton lifetime (
==== Oil solutions ==== Oil solutions are solutions of a compound with oil, for instance sesame oil or castor oil. When free steroids like estradiol are administered in oil solution by intramuscular injection, they are rapidly absorbed and the duration is relatively short. A single 1 to 2 mg dose of estradiol in oil solution by intramuscular injection has a duration of about 1 or 2 days. Little prolongation of duration is achieved with the use of larger doses. Nonetheless, the duration of estradiol in oil solution by intramuscular injection is significantly longer than an intravenous injection of estradiol or estradiol valerate, which show a duration of only a few hours. Conversely, intramuscular injections of estradiol esters in oil solution have durations of days to months, depending on the ester administered. Following a single 4 or 5 mg intramuscular injection in oil solution, peak estradiol levels are about 950 pg/mL with estradiol benzoate after 2 days, 400 to 650 pg/mL with estradiol valerate after 2 days, and 250 to 350 pg/mL with estradiol cypionate after 4 days. The durations with a 5 mg dose are 4 or 5 days with estradiol benzoate, 7 or 8 days with estradiol valerate, and 11 to 14 days with estradiol cypionate. The differences in estradiol levels and the different durations with estradiol levels are due to their different rates of release from the oily depot at the injection site. The longer and hence more lipophilic the fatty acid ester, the slower the release from the depot, the lower the peak estradiol levels, and the longer the duration.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.